glp 1 agonists with cardiovascular benefit Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists

FDA issued 25 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of

24.49

★★★★☆4.4 (179)

New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our

25.83

★★★★★4.9 (299)

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

21.79

★★★★★4.5 (176)

Buyer beware. New data points to a higher likelihood of adverse events from using compounded GLP-1 meds versus the fda approved branded versions. No I dong get paid by these companies. In fact the

25.32

★★★★★4.7 (257)

Glucagon Like Peptide 1 [7-36] Amide - an overview

25.02

★★★★★4.0 (19)

GLP-1 Agonists: Managing Employee Health and Employer Costs

29.84

★★★★★4.4 (112)

GLP-1 costs rise, but there are ways to save on weight-loss drugs

29.51

★★★★★4.6 (130)